Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Stoke Therapeutics, Inc. (STOK : NSDQ)

• Company Description    Stoke Therapeutics Inc. is a biopharmaceutical company. It develops antisense oligonucleotide medicines to treat genetic diseases. The company's product candidate consists of STK-001 which is to treat Dravet syndrome, a severe and progressive genetic epilepsy. Stoke Therapeutics Inc. is based in Bedford, Massachusetts. Number of Employees: 170

• Price / Volume Information    Yesterday's Closing Price: $30.05 Daily Weekly Monthly 20 Day Moving Average: 786,364 shares Shares Outstanding: 64.53 (millions) Market Capitalization: $1,939.01 (millions) Beta: 1.23 52 Week High: $40.22 52 Week Low: $20.32 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -8.83% -8.18% 12 Week 3.09% 0.91% Year To Date -5.32% -15.54%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 45 WIGGINS AVENUE - BEDFORD,MA 01730 USA ph: 781-430-8200 fax: - ir@stoketherapeutics.com http://www.stoketherapeutics.com

• General Corporate Information    Officers Ian F. Smith - Chief Executive Officer and Director Arthur O. Tzianabos - Chairman of the Board of Directors Thomas E. Leggett - Chief Financial Officer Julie A. Smith - Director Seth L. Harrison - Director Peer Information Stoke Therapeutics, Inc. (CORR.) Stoke Therapeutics, Inc. (RSPI) Stoke Therapeutics, Inc. (CGXP) Stoke Therapeutics, Inc. (BGEN) Stoke Therapeutics, Inc. (GTBP) Stoke Therapeutics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 86150R107 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/26 Next Expected EPS Date: 11/03/26 Share - Related Items Shares Outstanding: 64.53 Most Recent Split Date: (:1) Beta: 1.23 Market Capitalization: $1,939.01 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.88 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-3.52 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/03/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 5.61 Price/Cash Flow: - Price / Sales: 70.28 EPS Growth vs. Year Ago Period: -132.50% vs. Previous Quarter: -17.72% Sales Growth vs. Year Ago Period: -32.51% vs. Previous Quarter: 49.70% ROE 06/30/26 - -59.36 03/31/26 - -48.84 12/31/25 - -2.05 ROA 06/30/26 - -51.46 03/31/26 - -42.27 12/31/25 - -1.75 Current Ratio 06/30/26 - 7.69 03/31/26 - 8.99 12/31/25 - 5.28 Quick Ratio 06/30/26 - 7.69 03/31/26 - 8.99 12/31/25 - 5.28 Operating Margin 06/30/26 - -753.60 03/31/26 - -529.20 12/31/25 - -3.73 Net Margin 06/30/26 - -753.60 03/31/26 - -529.20 12/31/25 - -3.73 Pre-Tax Margin 06/30/26 - -758.23 03/31/26 - -533.18 12/31/25 - -3.73 Book Value 06/30/26 - 5.36 03/31/26 - 6.34 12/31/25 - 6.17 Inventory Turnover 06/30/26 - - 03/31/26 - - 12/31/25 - - Debt-to-Equity 06/30/26 - 0.00 03/31/26 - 0.00 12/31/25 - 0.00 Debt-to-Capital 06/30/26 - 0.00 03/31/26 - 0.00 12/31/25 - 0.00

Powered by Zacks Investment Research ©